Immuneering (IMRX) Net Cash Flow (2020 - 2026)

Immuneering's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$81.3 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 29045.69% year-over-year to -$81.3 million in Q1 2026; TTM through Mar 2026 was $11.5 million, a 137.66% increase from a year earlier, with the FY2025 full-year figure at $92.5 million, up 497.66% from the prior year.
• Net Cash Flow grew to -$81.3 million in Q1 2026 per IMRX's latest filing, from -$98.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $201.2 million in Q3 2025 and bottomed at -$98.9 million in Q4 2025.
• The 5-year median for Net Cash Flow is -$6.6 million (2024), against an average of -$1.6 million.
• Across the five-year window, Net Cash Flow soared 1485.45% in 2025 and slumped 29045.69% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$3.8 million in 2022, then tumbled by 128.37% to -$8.6 million in 2023, then retreated by 4.94% to -$9.1 million in 2024, then plunged by 991.71% to -$98.9 million in 2025, then climbed by 17.79% to -$81.3 million in 2026.
• Per Business Quant, the three latest IMRX Net Cash Flow figures stand at -$81.3 million (Q1 2026), -$98.9 million (Q4 2025), and $201.2 million (Q3 2025).